FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to a polypeptide biomarker of the effectiveness of the use of an FGFR inhibitor in the treatment of bladder cancer and lung cancer, which can be used in medicine.
EFFECT: use of a hybrid polypeptide in accordance with the present invention as a biomarker in the treatment of malignant tumours, based on the FGFR inhibitor, enables to avoid side effects during the treatment of a malignant neoplasm and to monitor the therapeutic state of the patient to obtain the best therapeutic effect in comparison with known therapeutic agents.
13 cl, 13 dwg, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMINOPYRAZOLE DERIVATIVE | 2010 |
|
RU2580543C9 |
| PHARMACEUTICAL COMPOSITION COMPRISING AMINOPYRAZOLE DERIVATIVE | 2014 |
|
RU2684618C2 |
| PYRAZOLOPYRIDINES AND ANALOGUES THEREOF | 2004 |
|
RU2426734C2 |
| FGFR AND ITS MUTATION INHIBITOR, METHOD OF ITS PREPARATION AND USE | 2021 |
|
RU2811207C1 |
| INDOL-3-YL-CARBONYL-PIPERADINE-BENZIMIDAZOLE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | 2006 |
|
RU2415139C2 |
| USING IkB KINASE INHIBITOR IN ANESTHETIZING TREATMENT | 2003 |
|
RU2320338C2 |
| ACRYLANILIDE DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN PHARMACOLOGY | 2016 |
|
RU2742372C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING BENZODIAZEPINE DERIVATIVES AND RSV FUSION PROTEIN INHIBITOR | 2005 |
|
RU2388476C2 |
| UREA COMPOUND, A METHOD FOR PRODUCTION THEREOF AND MEDICAL USE THEREOF | 2017 |
|
RU2741596C2 |
| SUBSTITUTED INDOLES | 2000 |
|
RU2255087C2 |
